1: Watanabe D, Iihara H, Kobayashi R, Fujii H, Mori R, Kumada K, Shimizu M, Futamura M, Suzuki A. Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis. Front Oncol. 2024 Jul 26;14:1414037. doi: 10.3389/fonc.2024.1414037. 2: Ostwal V, Ramaswamy A, Mandavkar S, Bhargava P, Naughane D, Sunn SF, Srinivas S, Kapoor A, Mishra BK, Gupta A, Sansar B, Pal V, Pandey A, Bonda A, Siripurapu I, Muddu VK, Kannan S, Chaugule D, Patil R, Parulekar M, Dhanawat A, Trikha M, Ghosh J, Noronha V, Menon N, Patil V, Prabhash K, Olver I. Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial. JAMA Netw Open. 2024 Aug 1;7(8):e2426076. doi: 10.1001/jamanetworkopen.2024.26076. 3: Liu Y, Hu P, Jiang Y, Chen X, Li S. Low dose of dexamethasone combined with netupitant and palonosetron in preventing nausea and vomiting in breast cancer patients induced by anthracycline drugs. Clin Transl Oncol. 2024 Jul 13. doi: 10.1007/s12094-024-03581-7. Epub ahead of print. 19(6):e0305913. doi: 10.1371/journal.pone.0305913.
合成参考文献
参考文献:10.1107/s1600536807007829 摘要:Ravikumar K, Sridhar B. An orthorhombic polymorph of palonosetron hydrochloride. Acta Crystallogr E Struct Rep Online. 2007 Feb 23;63(3):o1404–6. doi: 10.1107/s1600536807007829.